Position in ABVX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,158,911
-$11,459,262 QoQ
Shares Held
31,209
-77.7% QoQ
Ownership
0.036%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#117
of 301 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$49,439,460
CallShares
371,000
PutValue
$30,276,672
PutShares
227,200
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026ExodusPoint Capital Management, LP holds $275,349,927 across 101 Biotechnology names. ABVX ranks #20 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CYTK |
Cytokinetics Inc
|
249,259 | $21,234,374 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
224,927 | $16,752,562 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
148,212 | $14,105,336 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
361,126 | $14,087,525 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
53,201 | $12,819,844 | |
| 6 | NAMS |
NewAmsterdam Pharma Co N.V.
|
304,334 | $10,313,879 | |
| 7 | TGTX |
Tg Therapeutics, Inc.
|
164,513 | $9,038,344 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
336,567 | $8,656,503 |
All Filings in ABVX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $30,276,672 | 227,200 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $4,158,911 | 31,209 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $49,439,460 | 371,000 | Call | Sole | 2026-08-14 | |
| 2026-03-31 | $5,868,145 | 52,700 | Call | Sole | 2026-05-14 | |
| 2026-03-31 | $15,618,173 | 140,262 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $29,030,640 | 215,273 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $4,881,751 | 36,200 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||